FlyteHealth

FlyteHealth Co-Founder Dr. Katherine Saunders, MD, FTOS joined Good Morning America to discuss an important and often overlooked topic: how GLP-1 medications may affect fertility and contraception. At FlyteHealth, we believe cardiometabolic care must go beyond the prescription. Our comprehensive clinical model addresses each patient’s broader health needs—including reproductive goals, contraception, and pregnancy planning—to support safe, personalized treatment. Thank you to Good Morning America and ABC News for highlighting this important conversation. Watch the segment: https://lnkd.in/eska6TZG

Weight loss medications may support weight loss. Sustainable outcomes often depend on more than treatment alone. As employers and health plans navigate rising healthcare costs and growing demand for effective weight management solutions, the focus is shifting from treatment alone to strategies that support lasting engagement and long-term success. Join Katherine Saunders, MD, FTOS Co-Founder of FlyteHealth, and Emily Roberts, Chief Sales Officer, ForeverFit by Tivity Health, for a live discussion hosted by Shortlister exploring how connecting clinical care with fitness engagement may help improve outcomes while managing costs. Registration is still open! Register now: https://lnkd.in/gdCX9CH8

One year ago, CMS challenged health tech to move beyond pledges and deliver working, patient-first solutions. Yesterday in Washington, D.C., FlyteHealth was recognized for doing exactly that. We're among the first companies to achieve General Availability in the CMS Health Technology Ecosystem — Diabetes & Obesity category. Getting there meant clearing some of digital health's highest bars: verified identity, health records retrieved from CMS-Aligned Networks without a single portal login, and patients in full control of what data they share. The bottom line: Medicare beneficiaries can access connected, personalized eCKM care from FlyteHealth today. Pictured: Ishraf Ahmad and Darin Moore at the Hubert H. Humphrey Building. Full announcement: https://lnkd.in/djeCYeqn

Tomorrow, join our co-founder, Dr. Katherine Saunders, MD, FTOS on the Weight & Measure Podcast with Ted Kyle and Zachary Niemiec to discuss one of the most important conversations in obesity medicine today. GLP-1 medications are reshaping more than treatment—they're changing how we understand obesity, deliver care, and think about long-term health. From the latest research to responsible prescribing and the future of personalized care, this discussion will explore why comprehensive obesity treatment goes far beyond a prescription. 📅 Tuesday, July 28 at 7:00 p.m. ET Join the live conversation here: https://lnkd.in/en2_ZTUU #ObesityMedicine #GLP1 #ObesityCare #CardiometabolicHealth #WeightAndMeasure #FlyteHealth

The latest edition of FlyteHealth Insights is here! This month, we're highlighting the growing momentum behind integrated early cardio-kidney-metabolic (eCKM) care—including our participation in the Medicare GLP-1 Bridge, the Digital Medicine Society (DiMe) Seal for quality and trust, and new research reinforcing why GLP-1 access must be paired with comprehensive clinical care. We’re also sharing how FlyteHealth is expanding access, supporting lasting behavior change, and helping organizations improve outcomes while managing total cost of care. Read the July edition below. ⬇️

Lasting health outcomes require more than treatment alone. Regular movement, personalized support, and sustainable behavior change can improve overall health and well-being, with weight loss medications—including GLP-1s—used when clinically appropriate. As employers and health plans navigate rising healthcare costs and growing demand for effective solutions, the focus is shifting toward comprehensive care that supports long-term results. Join our co-founder Dr. Katherine Saunders, MD, FTOS, and Chief Sales Officer at Tivity Health, Emily Roberts, for a live discussion hosted by Shortlister exploring how connecting clinical care with fitness engagement can help improve outcomes, support long-term success, and manage costs. Register today:  https://lnkd.in/gdCX9CH8

Cardio-kidney-metabolic (CKM) syndrome just got its first-ever clinical guidelines. The American Heart Association and American College of Cardiology, alongside the American Society of Nephrology and American Diabetes Association, released joint guidance this month on diagnosing, staging, and treating CKM syndrome. A few highlights: ✔️ Annual screening for all adults on BMI + waist circumference, not BMI alone ✔️ Broader kidney testing (eGFR for everyone, UACR for stage 2+) to catch CKD earlier ✔️ The new PREVENT risk equations to guide treatment decisions, including when to start GLP-1 or SGLT2 therapy ✔️ A 5-stage framework (0–4) that treats each stage as a window for earlier intervention This is the model FlyteHealth was built on: catching cardiometabolic risk early and treating it as a single connected system rather than a set of separate conditions. Glad to see the field formalize it. Full JAMA article: https://lnkd.in/gPdJj82X #CKMSyndrome #CardiometabolicHealth #ObesityCare #Nephrology #Cardiology #eCKM #earlycardiokidneymetabolic

This week, it was announced that our co-founder, Dr. Katherine Saunders, MD, FTOS, will receive the 2026 Impact Award from the Women's Business Development Council (WBDC)! 💙 She'll be honored at WBDC's Women Rising Gala & Awards Celebration on Friday, October 23, recognizing nearly 30 years of WBDC's work helping women launch, grow, and scale businesses across Connecticut. Katherine's award centers on a message that drives everything we do at FlyteHealth: health access is economic access. Evidence-based cardiometabolic care doesn't just improve health outcomes, it helps people stay in the workforce, care for their families, and fully participate in their lives. Health and economic opportunity are inextricably linked. We're so proud of Katherine and grateful to WBDC for this incredible honor. Join us in celebrating her and the women leaders and entrepreneurs WBDC supports every day. More information on tickets, sponsorship, and opportunities: https://lnkd.in/eqh42SFU #WomenRisingGala #ImpactAward #WomenInBusiness #HealthAccessIsEconomicAccess #CardiometabolicHealth #WomenInMedicine #FlyteHealth #WomensBusinessDevelopmentCouncil

Employers aren't cutting GLP-1 coverage. They're just done writing blank checks for it. Employer coverage is holding flat at 36% even as pill forms make GLP-1s easier to prescribe than ever. Access isn't the bottleneck anymore — trust is. The real ask from benefits leaders isn't "cover GLP-1s or not." It's "prove appropriate use and cost containment." That's a program design problem, not a coverage problem — and it's why whole-person, physician-managed care beats point solutions that just dispense medication. That's the gap FlyteHealth is built to close. Our clinically-led teams manage GLP-1 and non-GLP-1 medication strategically alongside the whole cardiometabolic picture — hypertension, cholesterol, prediabetes, and more — so employers get appropriate prescribing and measurable cost control, not just a prescription pipeline. Benefits leaders: would more access move you, or better proof of appropriate use? #CardioKidneyMetabolic #GLP1 #EmployeeBenefits #ValueBasedCare #ChronicDiseaseManagement

Two weeks ago, we shared that nearly 90% of U.S. adults have at least one risk factor for cardiovascular-kidney-metabolic (CKM) syndrome. This week, The Washington Post brought that statistic to a national audience—highlighting a condition that is changing how we approach chronic disease. The timing is notable. In June 2026, the American Heart Association published its first clinical guidelines for identifying and staging CKM syndrome, establishing a standardized framework for earlier detection and intervention. A few key takeaways: ➡️ CKM is interconnected. Obesity, hypertension, diabetes, kidney disease, and cardiovascular disease share common drivers and shouldn't be managed in silos. ➡️ Early identification matters. The new four-stage framework emphasizes preventing disease progression before serious complications occur. ➡️ Treatment is becoming more integrated, combining lifestyle intervention with evidence-based therapies that improve outcomes across multiple organ systems. At FlyteHealth, this is how we've approached cardiometabolic care from the beginning—treating the whole patient across the cardio-kidney-metabolic continuum. Read the full article from The Washington Post: https://lnkd.in/gWdpfZWA #CKM #CardiometabolicHealth #ObesityCare #PopulationHealth #ValueBasedCare #FlyteHealth